Human-oriented and mechanism innovation to promote the open sharing of large-scale instruments and equipment

提出通过加强队伍建设来促进贵重仪器设备的开放共享工作。针对实验工程技术队伍中存在的问题,提出相应的各种举措,从调整职称评价体系、设立专项基金、建立新的激励机制、加强培训、优化人员队伍结构、参与共享平台建设等方面入手,通过实验工程技术人员队伍素质和服务能力的提高,从而提高贵重仪器设备的使用率和开放共享率。This paper puts forward the facilitation of the open sharing for large-scale instruments and equipment by strengthening the technician team 's construction.Corresponding measures are presented to resolve the problems of technician team,including reforming evaluation system,setting up special funds,innovating system,enhancing training,optimizing the structure of the team and building an open-sharing platform.The utilization and open sharing rates of large-scale instruments and equipment will be increased by the improvement of technicians's quality and services capabilities

A STUDY ON NANO-HYDROXYAPATITE-CHITOSAN SCAFFOLD FOR BONE TISSUE ENGINEERING

作者单位: 1 中国医学科学院中国协和医科大学生物医学工程研究所天津市生物医学材料重点实验室( 天津, 300192 ) ; 2 厦门大学生物医学工 程研究中心厦门大学医学院厦门市生物医学工程技术研究中心 通讯作者: 张其清, 教授, 博士导师, 研究方向: 组织引导再生, E-mail: zhangqiq@ xmu . edu. cn[中文文摘]目的以一种简单、有效的方法制备多孔的纳米羟基磷灰石(nano hydroxyapatite,nano-HA)-壳聚糖(chitosan,CS)复合支架,并评价其理化性能及与细胞相容性。方法采用原位复合-冷冻干燥方法,制备多孔nano-HA-CS支架。通过扫描电镜、透射电镜、X线衍射和傅立叶红外光谱分析支架的微观形貌及材料的组成。分离初生Wistar大鼠的成骨细胞,取传代培养第3代细胞分别与nano-HA-CS支架和纯CS支架共培养2、4、6、8h,各时间点各取4个样品,测定细胞在支架上的黏附率,并通过组织化学染色、扫描电镜观察细胞形态。结果nano-HA-CS复合支架具有多孔结构,孔径为100~500μm,大多数孔径为400~500μm。具有很高的孔隙率,随CS和HA含量的增加,孔隙率明显降低,密度升高。扫描电镜和透射电镜观察显示合成的HA晶体,晶粒大小为纳米级,在支架孔壁上均匀、连续分布如“铺路石”样。X线衍射和红外光谱分析表明合成的HA是含CO32-弱结晶纳米晶体。细胞相容性实验显示,成骨细胞在支架上黏附、增殖,并分泌纤维状细胞外基质;在复合支架上的黏附率明显高于纯CS支架。结论采用原位复合与冷冻干燥法结合制备的nano-HA-CS复合支架具有良好的理化性质和细胞相容性,有望应用于组织工程骨的构建。[英文文摘] Objective To fabricate a nano-hydroxyapatite-chitosan (nano-HA-CS) scaffold with high porosity by a simple and effective technique and to evaluate the physical and chemical properties and the cytocompatibility of the composite scaffold. Methods The three-dimensional nano-HA-CS scaffolds with high porosity were prepared by the in situ hybridization-freeze-drying method. The microscopic morphology and components of the composite scaffolds were analyzed by the scanning electron microscopy (SEM), the transmission electron microscopy(TEM), the X-ray diffraction(XRD)examination, and the Fourier transformed infrared spectroscopy(FTIR). The calvarial osteoblasts were isolated from the neonatal Wistar rats. The serial subcultured cells (3rd passage) were respectively seeded onto the nano-HA-CS scaffold and the CS scaffold, and then were co-cultured for 2, 4, 6 and 8 hours. At each time point, four specimens from each matrix were taken to determine the cell-adhesion rate. The cell morphology was observed by the histological staining and SEM. Results The macroporous nano-HA-CS scaffolds had a feature of high porosity with a pore diameter from 100 to 500 μm (mostly 400-500 μm). The scaffolds had a high interval porosity; however, the interval porosity was obviously decreased and the scaffold density was increased with an increase in the contents of CS and HA. The SEM and TEM results showed that the nano-sized HA was synthesized and was distributed on the pore walls homogeneously and continuously. The XRD and FTIR results showed that the HA crystals were carbonate-substituded and not well-crystallized. The cytocompatibility test showed that the seeded osteoblasts could adhere the scaffolds, proliferating and producing the extracellular matrix on the scaffolds. The adherence rate for the nano-HA-CS scaffolds was obviously higher than that for the pure CS scaffolds. Conclusion The nano-HA-CS scaffolds fabricated by the in situ hybridization-freeze-drying method have a good physical and chemical properties and a good cytocompatibility; therefore, this kind of scaffolds may be successfully used in the bone tissue engineering.天津市科技攻关项目资助项目(05YFGZGX03800

Strengthening Argumentation Before Purchasing Expensive Equipments to Exert the Maximum Investment Benefits

近几年来,我国大学先进设备的质和量都有大幅度提高。如何管理这些贵重的先进设备并使其投资效益最大化已成为倍受关注的问题。该方法通过采用邀请校外专家参与仪器设备购置前论证、建立院系及学校两级评估体系等措施,保证仪器设备资金投入以满足高水平研究课题的需要。How to manage university's expensive advanced equipments and make the investment benefits maximized is of great concern.Several measures,such as,experts from other universities or outside were invited to took part in pre-purchase argumentation of those equipments,school and university two level evaluation systems and so on,were taken to make sure that the investment could meet the requirement for high level subjects

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

JUNO Sensitivity on Proton Decay p→νˉK+p\to \bar\nu K^+ Searches

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this paper, the potential on searching for proton decay in $p\to \bar\nu K^+$ mode with JUNO is investigated.The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits to suppress the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar\nu K^+$ is 36.9% with a background level of 0.2 events after 10 years of data taking. The estimated sensitivity based on 200 kton-years exposure is $9.6 \times 10^{33}$ years, competitive with the current best limits on the proton lifetime in this channel

JUNO sensitivity on proton decay p → ν K + searches*

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this study, the potential of searching for proton decay in the $p\to \bar{\nu} K^+$ mode with JUNO is investigated. The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits suppression of the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar{\nu} K^+$ is 36.9% ± 4.9% with a background level of $0.2\pm 0.05({\rm syst})\pm$$0.2({\rm stat})$ events after 10 years of data collection. The estimated sensitivity based on 200 kton-years of exposure is $9.6 \times 10^{33}$ years, which is competitive with the current best limits on the proton lifetime in this channel and complements the use of different detection technologies